On July 31, 2023 Invectys, Inc., a clinical-stage immuno-oncology company focused on developing novel therapies for advanced cancers, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its revolutionary product, IVS-3001 (Press release, Invectys, JUL 31, 2023, View Source [SID1234633544]). This significant milestone marks a crucial step forward in advancing cancer treatment options and improving patient outcomes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IVS-3001 is a cutting-edge CAR-T cell immunotherapy that targets the rarely exploited immune checkpoint and tumor-specific antigen known as HLA-G. This molecule, typically expressed only during pregnancy, protects the fetus from the mother’s immune system. However, in cancer, HLA-G can be utilized by tumors to create a protective microenvironment, evading the immune system, and promoting tumor growth. By targeting this mechanism, IVS-3001 aims to reinvigorate the body’s natural defense to combat cancer effectively.

The Fast Track designation to IVS-3001 was based on the compelling data from the Investigational New Drug Application (IND) submission, and the potential for addressing the unmet need in patients with HLA-G positive locally advanced or metastatic clear cell renal cell carcinoma (RCC) who have failed or are intolerant to standard RCC therapies.

Fast Track designation is a critical regulatory designation designed to expedite the development and review process for therapies that address unmet medical needs in serious conditions.

« We are thrilled to receive the FDA’s Fast Track designation for IVS-3001, » said Dr. Jake Kushner, CEO of Invectys. « This recognition further validates the potential of our CAR-T cell therapy in revolutionizing cancer treatment for patients with solid tumors. The dedicated team at Invectys, as well as our partners, are committed to bringing this innovative therapy to the clinic and making a meaningful difference in the lives of cancer patients. »

For more information on Invectys, Inc. and its revolutionary CAR-T cell immunotherapy, please visit www.invectys.com.